Skip to main content

Advertisement

Table 4 Results of the logistic regression models on the risk of hospital/ED associated CINV events

From: Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study

Parameter Breast cancer (N = 3606) Carboplatin-treated Lung cancer (N = 4497) Cisplatin-treated lung cancer (N = 1154)
  OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
age NS NS NS NS NS NS
CCI 1.247 (1.122-1.387) <.0001 1.042 (1.012-1.073) 0.0052 NS NS
Gender (male as reference)
Female NA NA 0.817 (0.678-0.985) 0.0338 NS NS
Days with cyclophosphamide (in breast cancer) or carboplatin or cisplatin (in lung cancer) treatment 0.719 (0.619-0.836) <.0001 0.942 (0.915-0.969) <.0001 NS NS
Antiemetic regimen (older 5-HT3 RAs as reference)
Palonosetron 0.618 (0.447-0.854) 0.0035 0.712 (0.586-0.864) 0.0006 0.707 (0.514-0.972) 0.0330
  1. NA: not applicable, NS: Not significant.